ES2401904R1 - RECOMBINING VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE GEN C6L, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. - Google Patents

RECOMBINING VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE GEN C6L, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.

Info

Publication number
ES2401904R1
ES2401904R1 ES201131230A ES201131230A ES2401904R1 ES 2401904 R1 ES2401904 R1 ES 2401904R1 ES 201131230 A ES201131230 A ES 201131230A ES 201131230 A ES201131230 A ES 201131230A ES 2401904 R1 ES2401904 R1 ES 2401904R1
Authority
ES
Spain
Prior art keywords
mva
aids
diseases
vaccines against
against hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201131230A
Other languages
Spanish (es)
Other versions
ES2401904B1 (en
ES2401904A2 (en
Inventor
Arriaza Juan Francisco Garcia
Rodriguez Carmen Elena Gomez
Rodriguez Mariano Esteban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201131230A priority Critical patent/ES2401904B1/en
Priority to PCT/ES2012/070521 priority patent/WO2013011179A2/en
Publication of ES2401904A2 publication Critical patent/ES2401904A2/en
Publication of ES2401904R1 publication Critical patent/ES2401904R1/en
Application granted granted Critical
Publication of ES2401904B1 publication Critical patent/ES2401904B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vectores recombinantes basados en el virus modificado de Ankara (MVA), con deleción en el gen C6L, como vacunas contra el VIH/SIDA y otras enfermedades. La presente invención se engloba dentro de los campos de la biología molecular y de la biotecnología. Específicamente se refiere a virus recombinantes basados en el virus modificado de Ankara (MVA) que expresan los antígenos gp120 y Gag-Pol-Nef del virus de la inmunodeficiencia humana (VIH-1) de subtipo B (MVA-B), sobre los que se ha delecionado el gen de vaccinia C6L, y que han sido diseñados para utilizarse como vacunas contra el VIH/SIDA y otras enfermedades.Recombinant vectors based on the modified Ankara virus (MVA), with deletion in the C6L gene, as vaccines against HIV / AIDS and other diseases. The present invention falls within the fields of molecular biology and biotechnology. Specifically it refers to recombinant viruses based on the modified Ankara virus (MVA) that express the gp120 and Gag-Pol-Nef antigens of the human immunodeficiency virus (HIV-1) of subtype B (MVA-B), on which The C6L vaccinia gene has been deleted, and they have been designed to be used as vaccines against HIV / AIDS and other diseases.

ES201131230A 2011-07-19 2011-07-19 RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES. Expired - Fee Related ES2401904B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201131230A ES2401904B1 (en) 2011-07-19 2011-07-19 RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.
PCT/ES2012/070521 WO2013011179A2 (en) 2011-07-19 2012-07-11 Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201131230A ES2401904B1 (en) 2011-07-19 2011-07-19 RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.

Publications (3)

Publication Number Publication Date
ES2401904A2 ES2401904A2 (en) 2013-04-25
ES2401904R1 true ES2401904R1 (en) 2013-06-05
ES2401904B1 ES2401904B1 (en) 2014-04-07

Family

ID=47558548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201131230A Expired - Fee Related ES2401904B1 (en) 2011-07-19 2011-07-19 RECOMBINANT VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE C6L GEN, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.

Country Status (2)

Country Link
ES (1) ES2401904B1 (en)
WO (1) WO2013011179A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2010127115A1 (en) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2010127115A1 (en) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARCÍA-ARRIAZA, J. et al. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One. Agosto 2010, Vol. 5, Nº 8, Nº artículo: e12395. ISSN 1932-6203. *
GONZÁLEZ, J. M. et al. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virology Journal. Marzo 2010, Vol. 7, Nº 1, Nº artículo: 59. ISSN 1743-422X. *
GUERRA, S. et al. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. Journal of Virology. Agosto 2010, Vol. 84, Nº 16, páginas: 8141 - 8152. ISSN 1098-5514. *

Also Published As

Publication number Publication date
WO2013011179A2 (en) 2013-01-24
WO2013011179A3 (en) 2013-03-14
ES2401904B1 (en) 2014-04-07
ES2401904A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
CO2018006706A2 (en) Mutated viruses, method of preparation and use thereof
BR112018008090A2 (en) herpes simplex virus vaccine.
CL2017000780A1 (en) Compositions and methods to silence the expression of the hepatitis b gene virus
EA201591287A1 (en) VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE
EA201891186A1 (en) ANTIBODIES, NEUTRALIZING THE VIRUS OF HUMAN IMMUNODEFICIENCY
CL2018000432A1 (en) Therapeutic vaccines against hpv18
MA44059B1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
GT201500020A (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
BR112016020688A2 (en) COMPOSITIONS USEFUL IN THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC)
MX2016014642A (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof.
CO2017007105A2 (en) New tilapia viruses
MY173638A (en) Parainfluenza virus 5 based vaccines
CU20180035A7 (en) ATTENDED INFLUENZA VECTORS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES
EA201290956A1 (en) VACCINE AGAINST HIV
GT201600066A (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1
CL2018001946A1 (en) Attenuated viruses of infectious bronchitis.
MX2017009812A (en) Compositions and methods for inhibiting viral infection.
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
CO7461133A2 (en) Parvovirus 5a pig, methods of use and vaccine
NI201700080A (en) VACCINE COMPOSITIONS FOR DENGUE VIRUS AND METHODS OF USE OF THE SAME.
MX2019007924A (en) Influenza vaccines.
ES2401904R1 (en) RECOMBINING VECTORS BASED ON THE MODIFIED VIRUS OF ANKARA (MVA), WITH DELETION IN THE GEN C6L, AS VACCINES AGAINST HIV / AIDS AND OTHER DISEASES.
AR115070A1 (en) STEM CELLS CONTAINING A SYNTHETIC CHIMERICAL VACCINE VIRUS AND METHODS FOR ITS USE
MX2015010763A (en) H5 proteins of h5n1 influenza virus for use as a medicament.
CR20140432A (en) VIRUS OF THE MODIFIED MAREK'S DISEASE AND VACCINES PREPARED WITH THE

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2401904

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140407

FD2A Announcement of lapse in spain

Effective date: 20181015